Dr. Hsing-Mao Chu, VP of R&D at Immunwork is speaking at the 2nd Next-Generation Conjugates Summit in Boston next week. Dr. Chu will introduce our innovative antibody-radionuclide conjugate (ARC) technology platform and its application in pancreatic cancer diagnosis/treatment.
Join us at this exciting conference!

https://lnkd.in/ebgeZYk5

 
Back to the top